Compare TORO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TORO | SGMT |
|---|---|---|
| Founded | 2022 | 2006 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.5M | 169.4M |
| IPO Year | 2022 | 2021 |
| Metric | TORO | SGMT |
|---|---|---|
| Price | $5.04 | $7.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.13 |
| AVG Volume (30 Days) | 25.3K | ★ 998.3K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.64 | $4.50 |
| 52 Week High | $8.50 | $10.27 |
| Indicator | TORO | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 51.07 | 53.16 |
| Support Level | $4.87 | $7.04 |
| Resistance Level | $5.25 | $8.03 |
| Average True Range (ATR) | 0.17 | 0.46 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 56.67 | 46.77 |
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.